[go: up one dir, main page]

AR106647A1 - Compuesto piranodipiridínico - Google Patents

Compuesto piranodipiridínico

Info

Publication number
AR106647A1
AR106647A1 ARP160103430A ARP160103430A AR106647A1 AR 106647 A1 AR106647 A1 AR 106647A1 AR P160103430 A ARP160103430 A AR P160103430A AR P160103430 A ARP160103430 A AR P160103430A AR 106647 A1 AR106647 A1 AR 106647A1
Authority
AR
Argentina
Prior art keywords
formula
dipyridin
pyrano
dihydro
oxo
Prior art date
Application number
ARP160103430A
Other languages
English (en)
Inventor
Kamada Yasuaki
Fukuyama Takashi
Hirota Shinsuke
Kita Yoichi
Watanabe Toru
Shibuguchi Tomoyuki
Kotake Makoto
Ohashi Yoshiaki
Takeda Kunitoshi
Fukumoto Hironori
Kobayashi Yoshihisa
Shin Kogyoku
Yoshida Yu
Kurokawa Toshiki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR106647A1 publication Critical patent/AR106647A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto seleccionado del grupo constituido por: 9-(2-clorofenil)-7-(piridin-3-il)-6H-pirano[3,2-b:5,4-b’]dipiridin-8(7H)-ona de fórmula (1), 2-fluoro-6-(7-(5-metoxipiridin-3-il)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (2), 2-fluoro-6-(7-(6-metilpiridin-3-il)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (3), 9-(2-cloro-3-fluorofenil)-7-(6-metilpiridin-3-il)-6H-pirano[3,2-b:5,4-b’]dipiridin-8(7H)-ona, de fórmula (4), 2-fluoro-6-(7-(2-metoxipirimidin-5-il)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (5), 7-(piridin-3-il)-9-(2,3,5,6-tetrafluorofenil)-6H-pirano[3,2-b:5,4-b’]dipiridin-8(7H)-ona de fórmula (6), 3-(8-oxo-7-(tiofen-3-il)-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)picolinonitrilo de fórmula (7), 3-(8-oxo-7-(tiofen-3-il)-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)pirazino-2-carbonitrilo de fórmula (8), 9-(2-fluorofenil)-7-fenil-6H-pirano[3,2-b:5,4-b’]dipiridin-8(7H)-ona de fórmula (9), 2-(7-(4-fluorofenil)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (10), 3-(7-(4-fluorofenil)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)picolinonitrilo de fórmula (11), 3-(7-(2-fluorofenil)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)picolinonitrilo de fórmula (12), 3-(3-fluoro-8-oxo-7-fenil-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)picolinonitrilo de fórmula (13), 2-fluoro-6-(3-fluoro-8-oxo-7-(piridin-3-il)-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (14), 2-fluoro-6-(7-(5-fluoropiridin-3-il)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (15), 2-fluoro-6-(10-fluoro-3-oxo-4-(piridin-3-il)-4,5-dihidro-3H-cromeno[3,4-b]piridin-2-il)benzonitrilo de fórmula (16), 9-(2-cloro-3-fluorofenil)-7-(5-fluoropiridin-3-il)-6H-pirano[3,2-b:5,4-b’]dipiridin-8(7H)-ona de fórmula (17), 2-fluoro-6-(8-oxo-7-(pirimidin-5-il)-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (18), 3,6-difluoro-2-(8-oxo-7-(piridin-3-il)-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (19), 2-(7-(5-cloropiridin-3-il)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)-6-fluorobenzonitrilo de fórmula (20), 2-fluoro-6-(7-(2-metilpirimidin-5-il)-8-oxo-7,8-dihidro-6H-pirano[3,2-b:5,4-b’]dipiridin-9-il)benzonitrilo de fórmula (21) y 9-(3-fluoro-2-metilfenil)-7-(piridin-3-il)-6H-pirano[3,2-b:5,4-b’]dipiridin-8(7H)-ona de fórmula (22); o una de sus sales farmacéuticamente aceptables.
ARP160103430A 2015-11-13 2016-11-10 Compuesto piranodipiridínico AR106647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015222805 2015-11-13

Publications (1)

Publication Number Publication Date
AR106647A1 true AR106647A1 (es) 2018-02-07

Family

ID=58691331

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103430A AR106647A1 (es) 2015-11-13 2016-11-10 Compuesto piranodipiridínico

Country Status (24)

Country Link
US (1) US9738656B2 (es)
EP (1) EP3378863A4 (es)
JP (1) JP6353173B2 (es)
KR (1) KR20180080201A (es)
CN (1) CN108349989B (es)
AR (1) AR106647A1 (es)
AU (1) AU2016351424B2 (es)
BR (1) BR112018008006A2 (es)
CA (1) CA3002930A1 (es)
CL (1) CL2018001067A1 (es)
CO (1) CO2018004213A2 (es)
HK (1) HK1255832A1 (es)
IL (1) IL258952B (es)
JO (1) JO3742B1 (es)
MA (1) MA43275A (es)
MX (1) MX380080B (es)
MY (1) MY185971A (es)
PE (1) PE20181008A1 (es)
PH (1) PH12018500903A1 (es)
RU (1) RU2743998C2 (es)
SG (1) SG11201803433TA (es)
TW (1) TWI644916B (es)
UA (1) UA122241C2 (es)
WO (1) WO2017082288A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2018207715A1 (ja) * 2017-05-09 2020-03-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラノジピリジン化合物の結晶
WO2018207729A1 (ja) * 2017-05-09 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラノジピリジン化合物を含有する治療剤
JP7217259B2 (ja) * 2017-07-26 2023-02-02 エイチジーアンドエイチ ファーマスーティカルズ（ピーティワイ）リミテッド てんかん及び関連疾患を患う患者の予防及び治療のためのメセンブレノール及び／又はメセンブラノール
JP7250686B2 (ja) * 2017-10-06 2023-04-03 武田薬品工業株式会社 複素環化合物
US11447488B2 (en) 2017-10-06 2022-09-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds
CN111801096B (zh) 2018-03-20 2024-03-05 卫材R&D管理有限公司 癫痫治疗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0102046A1 (en) * 1982-08-26 1984-03-07 Schering Corporation Tricyclic lactams, method for making them, pharmaceutical compositions containing them
US4511569A (en) 1982-08-26 1985-04-16 Schering Corporation Tricyclic lactams and derivatives useful in increasing cardiac contractility
US4666916A (en) 1985-11-08 1987-05-19 Ciba-Geigy Corporation Hexahydro-(1)-benzo-(pyrano and thiopyrano) (4,3-C)pyridines, useful as serotin-2 blocking agents
FR2717811B1 (fr) * 1994-03-28 1996-04-26 Rhone Poulenc Rorer Sa Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
HU229553B1 (en) * 2000-06-12 2014-01-28 Eisai R & D Man Co 1,2-dihydropyridine compound, process for preparation of the same and use thereof
IL154709A0 (en) * 2000-09-18 2003-10-31 Eisai Co Ltd Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
RU2279428C2 (ru) * 2000-09-18 2006-07-10 Эйсай Ко., Лтд. Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов

Also Published As

Publication number Publication date
US20170137436A1 (en) 2017-05-18
MX2018004979A (es) 2018-09-07
RU2743998C2 (ru) 2021-03-01
BR112018008006A2 (pt) 2018-10-30
CO2018004213A2 (es) 2018-07-10
PH12018500903A1 (en) 2018-11-05
IL258952B (en) 2021-01-31
AU2016351424A8 (en) 2018-06-14
AU2016351424A1 (en) 2018-05-10
CN108349989A (zh) 2018-07-31
CL2018001067A1 (es) 2018-07-20
RU2018115716A3 (es) 2020-02-06
HK1255832A1 (zh) 2019-08-30
MA43275A (fr) 2018-09-26
RU2018115716A (ru) 2019-12-13
MY185971A (en) 2021-06-14
UA122241C2 (uk) 2020-10-12
JP6353173B2 (ja) 2018-07-04
US9738656B2 (en) 2017-08-22
CA3002930A1 (en) 2017-05-18
EP3378863A4 (en) 2019-03-06
MX380080B (es) 2025-03-11
PE20181008A1 (es) 2018-06-26
JPWO2017082288A1 (ja) 2017-12-21
SG11201803433TA (en) 2018-05-30
IL258952A (en) 2018-06-28
AU2016351424B2 (en) 2020-06-25
KR20180080201A (ko) 2018-07-11
JO3742B1 (ar) 2021-01-31
TW201720829A (zh) 2017-06-16
TWI644916B (zh) 2018-12-21
EP3378863A1 (en) 2018-09-26
WO2017082288A1 (ja) 2017-05-18
CN108349989B (zh) 2021-01-01

Similar Documents

Publication Publication Date Title
AR106647A1 (es) Compuesto piranodipiridínico
CL2021003064A1 (es) Formas en estado sólido
PE20161388A1 (es) Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
PE20170321A1 (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
ES2898938T3 (es) Compuestos de heteroarilpiridona y aza-piridona como inhibidores de la actividad Btk
PE20170693A1 (es) Derivados de imidazol pentaciclicos fusionados
PT3712152T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PL3371185T3 (pl) Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
MX2020012097A (es) Proceso para preparar inhibidores de tirosina cinasa de bruton (btk).
DK3230298T3 (da) 3-substituerede 5-amino-6H-thiazolo[4,5-d]pyrimidin-2,7-dion forbindelser til behandling og forebyggelse af virusinfektion
DK3416964T3 (da) 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
IL255901B (en) Crystal of (6s,9as)–n–benzyl–8–({6–[3–(4–ethylpiperazin–1–yl)azetidin–1–yl]pyridin–2–yl}methyl)–6–(2– fluoro-4-hyfroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h )-carboxamide
DK3873884T3 (da) 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
HUE052454T2 (hu) CDK4 inhibitorok 2-((5-(1-(3-(metilszulfonil)propil)piperidin-4-il)piridin-2-il)amino)-pirido[2,3-D]pirimidin-7(8H)-on származékok és rokonvegyületek tumorok kezelésére
DK3436463T3 (da) Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
MY199935A (en) Solid state forms of fused heteroaromatic pyrrolidinones
CL2019001454A1 (es) Productos combinados para el tratamiento del vsr (divisional de la solicitud n°1808-2018).
DK3400225T3 (da) Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner
MX387694B (es) Formulaciones farmaceuticas de inhibidores de cinasa relacionada con tropomiosina (trk).
MA46937A (fr) 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA45048A (fr) Nouveau dérivé de 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one
PH12016502271B1 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
RU2020128731A (ru) Средство для лечения эпилепсии

Legal Events

Date Code Title Description
FB Suspension of granting procedure